HUE032563T2 - IL-6 elleni ellenanyagok és alkalmazásuk - Google Patents

IL-6 elleni ellenanyagok és alkalmazásuk Download PDF

Info

Publication number
HUE032563T2
HUE032563T2 HUE08756095A HUE08756095A HUE032563T2 HU E032563 T2 HUE032563 T2 HU E032563T2 HU E08756095 A HUE08756095 A HU E08756095A HU E08756095 A HUE08756095 A HU E08756095A HU E032563 T2 HUE032563 T2 HU E032563T2
Authority
HU
Hungary
Prior art keywords
antibody
cell
cells
disease
ser
Prior art date
Application number
HUE08756095A
Other languages
English (en)
Inventor
Leon Garcia-Martinez
Anne Elisabeth Carvalho Jensen
Katie Olson
Ben Dutzar
Ethan Ojala
John Latham
Brian Kovacevich
Jeffrey T L Smith
Original Assignee
Alderbio Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alderbio Holdings Llc filed Critical Alderbio Holdings Llc
Publication of HUE032563T2 publication Critical patent/HUE032563T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)

Claims (3)

  1. SZA8 AOALM.I !Okik Y PONT* )K 1 ;\nîi-IL6 ellenanyag vagy ellenanyag fragment. amely tartalma* <i> egy variábilis könnyű láncot {Vü «mely tartalmaz egy CDRI polipepódeí, amely a 4. számú szekvenciának meg* téU'V ammosax, v’ek\en*oaM eh ec\ í UR' pohpepudet macisa N számú vekuuuanak megfő* lek* ammu-en áll. ce egv « íiRd poupeptmet, amely a 0 votmn vtesenesaual oergo léte uon-ov^ szekvemáábol all, és («) uuiáltMz egy steébilte nehéz láncot Αόρ, sínél?-tartalmaz egy CDRI polippildéL amely s l számú stmktebóláMk poitpépildét, amely tel. számú :^^gfnclÍp®á:m^étóó--;MiS^v s^ekvepeiiigk yt§p í jii;: sy# mű szekvenciának megfelelő anünosav szekvenciából áll, és egy CDR3 poltpepúden amely a 9. gzltnd :^eÄÄÄ megtblelö amioosáv szekvenciából áll. atel az ellenanyagunk vágy állandója kisebb, mim 50 pikomoh Bsacore-tíd nigghatarozva, 2 Az I. igénypont szerinti ellenanyag vagy ellenanyag iVagmetsse a) amely aglíkozilezett b) amely tan aie n.v egs te main: ug\ >ocgvthcoutxa dogs na g\ .»tewon ete Mos lim „ opi .. e <\y * \ es un. kerted el emel' egx b» n »m ♦ ellen nw ec' v» slum i elkm* \*<. ' λ\ - k «>» dim* &amp;$*$< itndy egy tetpgnifl etemmsag, macis egv nvui am.dunnn 11 m oneuanvagted szarrnazik, e) ameo vcv hkw' hetedik » ouu\tr seneUn n^pussz^«'«' y e mv e\s κο λ te s~ go IL-ó molekulákhoz ét cpry $ amé ly spéci tikusan kötőditek hnotin tejtilen vágy é-hoz egy olyan betegségben szenvedő hetegbeti:: abol az ILte szintek ntéptés el keekék. ahol a betegségei a következők közül választjuk ki: általános laradiság testgyakorlással nsdukált fáradtság, iákhoz kapcsolódó feudtság. gyulladásos megbetegedéshez kapcsolódé fáradtság, krimi* kos laradtsag szindróma, rákhoz kacsolódó cachexia, keringette káppolódö: cachexia, légzéssel te p^oiatuseJüSiMa, vese* *,z \ | <,s<te Mo ,. ete\ * eb tev w kd|\ te -,te- temem, reumán ane m»; szisztémás lopus erythematosus (büß), szisztémás rúnáikon idtopunas artfnttó, pszonazis, pszori&amp;tikus ardíropatú'g ypondylitss ankylopoctka. gyulladásos bclbetetoa-g (IBI», pobndglgia reumaiika. óriássejtes asteritk autoimmun ergyuüaclas, graft-versus-host betegség (GY HD) Sjogren szindróma, felnőttkorban fellépő Still betegség, osteoarthritis, oszieoporözis, s osont Hagel beiegsé··· gc mie'caea muloplcv öodgk e h nm no·'''' von souo rr o "vAäU" R x\ u xs’xsop rák. multi een tri kn a Castkman betegseg, petefészek rak. gyogyszenwriizumeia rak kemoterápiában,, rák kemoterápia toxicités, iszkemias sxlvhetegseg, aiheroszklerózis, elínzás, cukorbetegség, asztma, vkluw^ ínuitipkv -\itbeov ko,, c^ebu^r^Aok«''- bemgsee \.o., akit cos salas/ alkpiak V emu o -,. 'Jack-, nemi a a ó vnku-< b ,Α'μ u m magax v. so a Λμονχ m -,g·, kr Osakas betegséghez. kapcsolódó depresszió, trombózis, irombociíózix. akié aeisciegtetenscg, mifetlmiikiit szindróma. vetélés, krónikus prosztaíagyuíladás, |ai*.;^il&amp;#á§#s bebgi* seg. reperinxiós sérülés, transzplantatum kilökődés, madárbulnengmllmló, jànâft$$ft^dédZIéM> mótikon légzési elégtelenség szindróma CARDS), súlyos akm légzést szindróma {SARS), szépíts, szisztémás gyulladásos válasz szindróma {SIRS), egyrák, egy gyulladásos rendellenesség, egy Gratis rendeden*. ^ egy antvimmun seraldieneaseu, utlnius, cadiexta cs sótxadaxos ar.ndruma, g) amely kózv<4|pil vagy közvetve;|agcsglii|ik egy kimutatható jelöléshez vagy egy terápiás sxe?hex. b) ahol a 3 (e) pont szerűm szóban forgó khuéra ellenanyag egy hantán Fc4 tartalmaz, eukh a k<'M^oto vm sV tíad valavAhato ki kOt lgu„k IgGu IgGi, lgOs igtm IgtG igi'G ig09, IgGIO IgGl I, lgG12, IgGO, IgGi-k lgG1\ IgGbx IgGI? IgGIk, IgCjiR iá altot a szóban forgó ellenanyag megköt legalább egy oldható I.L-ó'-őb se)t%L^á:nen oipyxnllli *oi, Il öli oR, II ο II R„o ''i Wrtpievekct a\^*\ evk malomét t j) ahol a szobán forgó eljemmyagNm található Vs; vagy Y*. hmeok egy vagy több nyel IG se;t popé, sex mól s- ,mü,um *\ k) ahol a szóban forgó ellébánylg eéib fóbbéliéáík kőtésfipielitlssá! az őtóbálótÍleó&amp;: Ihez t$lí.-őR) vagy a gpl 30-hoz. !) aboi a szóban forgó ellenanyag gátolja az IL-6 ex ez IL-őR assioxoialódáxaí és· vagy a/ 0Ι,-6ό1,~6Κύφ11b komplexek termelődései, év-vagy az fL-b/IL-OR/gpl 30 multimerek termelódesÉ, nő aoi o A o loi go fogo\.v, vmaki-vf kő xauvttux k I ab „mgrn. χ le iagmeos, vagy FCab'k fragment. n) aíől a szóban forgó ellenanyag tartalmaz még egy Effektor egységet, amelyet a kös-et-kezek közül választhatunk ki: ti) egy kimutatható egység, amely lehet egy fluoreszcens festek, egy enzim, egy sznbsrtt-.it, ovo bsbimmtvi/eens anyag, eg\ radioaktiv anyag, vugs egx kmodommes/eeax am ay, vagy (g) eg\ omUoomiliN egvse^, aroeh lehet vhtptaudnt mu dm mono ogs cneto ife egy chotoxikti« smvagy «gy radioaktiv anyag, o) i|of a ^#|»m:forgô ellenanyag a tdagomzilfe egy \?agp pbfepillafe ILA s^fefsz%§® mpt^m^Ê:, MM. jl^ilpe^poo 'imwgSmßk M«tgy m iL-Mt*6R/gpip· mdümetjei biológiai hats sat p) aboi a szobán il ago dlenaovag kombik egs kneas is sags konfermaeios b o plophoz:, g) amely egy egyl&amp;aeà ellenanf^r amely. 1$|$: #%jpÀ%ïÂ^ IgpÄ, IgilP, es ozek kombinációk à Ajk I igénypont szerinti aMbtÎ.,6 ellenanyag, vagy annak ellenanyag iggmanse, amely sin,nemz eg> V* láncot es egy V« láncot es tartalmazza a 2 es i számú szekvenciának megtelek* immosäv szekvenciát a 2, es 18 számú szekvenciának megfelelő aminnsav szekvenciát á 2, éyjfe vs.vii5 -<a P- encvi ük negl elő mm v'\a \ do cm ,at a 2' es > wn s veeweneuimik metefelo *minosav szekvenciát a 20. és 18. számú sz#vegm|pak megfelelő mmnpfev fedcvdteiáb vagy m >o és 19 számú szekvenciának megfelelő a«s|iö» ^«kvenc% :vagy ezeknek egy ellenanyagig a- X , K mrs u ma e on aeeh « talmaz egy Ve latxm illetve ea\ %*« I meet es >hu » az ami-sósav szekvenciája, hogy legalább 90°o~ös vágy »i|ydbb;.g-ii^öl^4|áezekbe*.,
  2. 4. Núkfeínsgv sfekvenclfe:jpJély a^ felk Igénypontok bármelyike szerinti antl-humán il..- ó ellenanyagot, vagy annak ellenanyag íragtnens|í tartalmazza, ;1 Vektor, amely a 4 igénypont szerinti nukleinsav szekvenciát tartalmaz. b. Rekomb'máns sejt, amely az l-d igénypontok bármelyike szerinti ellenanyagot vagy iídlabpl feagfeénki expresszálja. 7 Oyógyászab vagy diagnosztikaí készítmény, amely legalább egy, az 1-3. igenypon-tok barmélylke szerimi IL~6 ellenanyagot vagy ellenanyag ilgmebsb valamltií egy gfogyáfeatilgg dlógadható hordozót tartalmaz I:, A ?.. igénypont szeri nti gyógyászai mgy dtagnosztikai készítmény, a) amely tartalmaz még legalább egy stabilizáló szert, b) amely hoblezve van, vagy pj mods eav vags tóim aoinli -o eslemnnagoí tataim*,» mneh tilalmaz t,<n ogs \ x láncot, amelynek az ammopv szekvenciája á3H,: !&amp;,. vaggb íidazárou szekvenciának felel magi es (b) tartalmaz eav V= láncot nmeivé <v \ mm ,kh szelve χ t> i 'ég' szarni ^οκ^ιν,«^m felelófep vagy egf ldfcilÂSÿâgot egy humanizált ellenanvapt vagy ypmaekódl spemáző bágmenst #; % v\ ' >geo\ λ>ο*ο'\ banned He mu cdonmtxj^ wgo album \ g l· ^muo vágy dlsgiÄilÄä veiként történő alkahnMâë cédára. It); Az I -3, |g#^)óiSöÍ Mfmtív ike szerinti eilenan\ ág vef^ e!!er»|ei fI§ntens Imfck náltnn egy gyógyír flSálIltássbao, vágy egy olyan szer efoaihtaaában. amelyet e§y kezelési eljárásban aikfdmaznafc. ri- Egy y igém yont szériáit ellenanyag vagy fmomeos te; apóm serkent történő A LA mhzÉM a lé. igénypont szeriéi;: ái| ekéi: a keadendö betegségit vágy llâplot a KóveiU-rók közöl válásijuk ki: áItaÍ|ndsstegÉSia|s, testgyakorlással ittíidillf Äadtsag. rákhoz kapcsolódé fáradtság, gyulladásos megbetegedeshez; kapcsolódó ükadtság, krónikus fáradtság szindróma, rákhoz kapcsolódó cachexia, kenogëshez kapcsolódó cachexia, iég/.exse! kapcsolatos cachexia, veséhez kapcsolódé cachexia, életkorhoz kapcsoló·' dó cnchfcia, reumás arthritis, srisztemás lupus erythematosus t$l E}; sris/tetnas fiatalkori ídiopáiás arthritis, pszorlazts. pszorkéikus itrlhropátiu, spondylitis asdxsis'»poetica, gyulladásos belbí-tegseg (IBP), poltmíalgta retmnüika, óriáxseites intends. autditnnun ergudiad&amp;s, inatVversns-host betegség íOVHD), Sjogren szindróma, felnőttkorban fellépő Süli betegesig, osxleuarthriüs, oszteojxsroris a csont Paget betegségé, oíMőíuu mmuph-x Hongéin litntemn. non-Hodgkin linubma, prosztatarák, leukémia, vescaejt rak, inultieentriimsCasriemae betegség, petefészek rák, kemoterápiában, rák kemoterápia toxicités, iszkémias sast betegség, atheroszklbróiriA :#?teág :#ök^· betegség, asztma. szkJerotns multiplex, Alzheimer kór, cerebrovasxktílàris betegség; láz, akut. taxis valasz, allergiák, anémia, gvulladas anémiáin ('krónikus betegség mtérmája), ntagas yétnyöiÉg del--ressxio, egy krónikus betegséghez kapcsolod« depresszió, trombózis, fcombocitózil* akut izlyelégté' lertseg, metabolikus szindróma, vetélés,. krónikus proszMagyuliadás, giotneruloneAtüse, kjipedenggi gyulladásos betegség, Kperftkios sérülés, íraosxglaoiápm kilökődés, madiflpllnefiza, huilé, jfe#· nyes inüuenza, felnőttkori légzési elégtelenség szindróma (ÂRDS), súlyos akut légzési szindróma (SAKS), szepszis, szisztémás gyulladásos válasz szindróma (SÍRS), arthritis, egy rák, egy lőtóhimdn rentkáknesség. vagv egy gyulladásos teudellenéÉiljgg b) ahoi a kozeles tartalmazza még más terápiás szer beadását vagv kezelést rómá|;;gmelyel:a köfétkec 0'\ , o cvtha.c^ \ xornen a.\< ,Λοΐΐ,ηφη, cito 'Wo getttcíama cl amit rák '.agy vsrusfeaoz.es mellékhatásának kezelésére használónk.
  3. 12. Egy ellenanyag vagy ellenanyag frogmens P igénypont szerinti alkalmazása, ahol az alkalmazás diagnosztikus m von képalkotás a) álnál a szóban tót go alkalmazás kimutatja. IL-**ot expusszulo sejtek jelenlétet, and •l·' m, hóm lemé uh o«o i exxp' ? * vu itt anü t n < t '' o tbc i « \b ü mm nov oLum b|tékohy éiennylsegei adunk be, s szobán forgó be&amp;das tartalmazza nteg fa<hoa*.ox UCh<^} v'5^ e-> ^eiv megkönnyíti az ellenanyag Îdmutatàsèï a* Π..-&amp;<* *xprefcfc*ak» koros miye>\en ^ gävseiye! Π,,-b-oi espresszaîô tárnotok vagy attetek kimutatáséi δ lehet nasxnálni» ,|s amelyet az IL~6*ot expresszálö sejtekhez kapcsolódó gyn|las||sps Nflyek jólealéilnyk tehet hasasnál«), vagy e) ahol az eredményeket egy megölelő kezelést sémi tefyézéséítek: megkönttyólsétl; lehet használni. F.gv ellenanyag vagy ellenanyag fragment 0 ókus szerként, «hoi •az alkalmazás diagnosztikus in vow képalkotás, ahol az alkalmazás ·% 11 6-ot expresszfdo hooo'oL xag> ittetek *> mim,iía$d vam ielcpexeso, vagy M á ou Vpressese o., J. >\Kohií 1 m ..\ou\.-go okopo ev
HUE08756095A 2007-05-21 2008-05-21 IL-6 elleni ellenanyagok és alkalmazásuk HUE032563T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92455007P 2007-05-21 2007-05-21

Publications (1)

Publication Number Publication Date
HUE032563T2 true HUE032563T2 (hu) 2017-09-28

Family

ID=40122295

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16195797A HUE043782T2 (hu) 2007-05-21 2008-05-21 IL-6 elleni antitestek és alkalmazásuk
HUE08756095A HUE032563T2 (hu) 2007-05-21 2008-05-21 IL-6 elleni ellenanyagok és alkalmazásuk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE16195797A HUE043782T2 (hu) 2007-05-21 2008-05-21 IL-6 elleni antitestek és alkalmazásuk

Country Status (29)

Country Link
US (4) US20100290993A1 (hu)
EP (2) EP2164514B1 (hu)
JP (4) JP5833823B2 (hu)
KR (3) KR101741731B1 (hu)
CN (2) CN101754772B (hu)
AU (1) AU2008254584B2 (hu)
BR (1) BRPI0811782A2 (hu)
CA (2) CA2688146C (hu)
CO (1) CO6241159A2 (hu)
CY (2) CY1119068T1 (hu)
DK (2) DK2164514T3 (hu)
EA (1) EA200901533A1 (hu)
ES (2) ES2721753T3 (hu)
HK (1) HK1138796A1 (hu)
HR (2) HRP20170038T1 (hu)
HU (2) HUE043782T2 (hu)
IL (4) IL202238A (hu)
LT (2) LT3187506T (hu)
MX (2) MX2009012492A (hu)
NO (2) NO344119B1 (hu)
NZ (2) NZ581596A (hu)
PL (2) PL2164514T3 (hu)
PT (2) PT3187506T (hu)
SG (1) SG183742A1 (hu)
SI (2) SI3187506T1 (hu)
TR (1) TR201905366T4 (hu)
TW (2) TWI561530B (hu)
WO (1) WO2008144763A2 (hu)
ZA (1) ZA200908770B (hu)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101239051B1 (ko) 2005-10-21 2013-03-04 추가이 세이야쿠 가부시키가이샤 심장질환 치료제
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
WO2008144763A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US20150050288A1 (en) * 2007-09-06 2015-02-19 The Johns Hopkins University Treatment of TH17-Mediated Autoimmune Disease Via Inhibition of Stat3
WO2009052454A2 (en) 2007-10-19 2009-04-23 University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
US8277804B2 (en) 2008-05-21 2012-10-02 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
AU2016250477B2 (en) * 2008-11-25 2018-07-05 Vitaeris Inc. Antagonists of IL-6 to raise albumin and/or lower CRP
AU2013203804B2 (en) * 2008-11-25 2016-10-13 Vitaeris Inc. Antibodies to il-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
EP2361095B1 (en) * 2008-11-25 2017-12-20 AlderBio Holdings LLC Antagonists of il-6 to raise albumin and/or lower crp
WO2010071610A1 (en) * 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
WO2010088444A1 (en) * 2009-01-29 2010-08-05 Medimmune, Llc Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
AU2010311567B2 (en) * 2009-10-26 2015-03-26 Chugai Seiyaku Kabushiki Kaisha Method for the production of a glycosylated immunoglobulin
AU2016250478A1 (en) * 2009-11-24 2016-11-17 Alder Biopharmaceuticals, Inc. Antibodies to IL-6 and use thereof
EP2504030A4 (en) * 2009-11-24 2013-06-26 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
ES2932398T3 (es) * 2010-05-28 2023-01-18 Chugai Pharmaceutical Co Ltd Potenciador de la respuesta de las células T antitumorales
EP2400298B1 (en) 2010-05-28 2013-08-14 F.Hoffmann-La Roche Ag Single B-cell cultivation method and specific antibody production
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
CN103619879A (zh) 2010-12-01 2014-03-05 奥尔德生物控股有限责任公司 抗ngf组合物及其用途
EP2646469B1 (en) * 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
US8597883B2 (en) 2011-02-14 2013-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for cancer-related fatigue and use thereof
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
EA033109B1 (ru) 2011-05-20 2019-08-30 Олдербайо Холдингз Ллк Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
SG194937A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as pichia pastoris
EA201891284A1 (ru) 2011-05-20 2018-11-30 Олдербайо Холдингз Ллк Композиции антител против cgrp и их применение
US10150968B2 (en) 2011-08-19 2018-12-11 Alderbio Holdings Llc Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
BR112014003841B1 (pt) * 2011-08-19 2022-02-15 H. Lundbeck A/S Método para identificar uma célula hospedeira diploide de pichia pastoris que produz um anticorpo desejado com uma maior pureza
EP2583980A1 (en) * 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
KR102069394B1 (ko) * 2011-11-23 2020-01-22 에프. 호프만-라 로슈 아게 Cd40l 발현 포유류 세포 및 그의 용도
EP2794652B1 (en) 2011-12-21 2017-11-15 F. Hoffmann-La Roche AG Rapid method for cloning and expression of cognate antibody variable region gene segments
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
LT4019041T (lt) 2012-07-13 2023-04-11 The Trustees Of The University Of Pennsylvania Toksiškumo, atsirandančio dėl car receptorių priešnavikinio aktyvumo, suvaldymas
CN104903349B (zh) * 2012-11-08 2018-10-19 十一生物治疗股份有限公司 Il-6拮抗剂及其应用
US9062104B2 (en) * 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
TWI670279B (zh) 2013-03-15 2019-09-01 美商艾爾德生物製藥股份有限公司 抗體純化及純度監測
CA2905180C (en) 2013-03-15 2023-03-07 Alder Biopharmaceuticals, Inc. Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
CA2916980C (en) 2013-07-03 2023-02-21 Alder Biopharmaceuticals, Inc. Regulation of glucose metabolism using anti-cgrp antibodies
CN105198982B (zh) * 2014-06-18 2019-07-26 上海交通大学 基于il-6的抗原表位及其应用
US11142571B2 (en) * 2014-11-07 2021-10-12 Sesen Bio, Inc. IL-6 antibodies
EP3835319A1 (en) 2014-12-19 2021-06-16 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
DE102016002298A1 (de) 2015-03-06 2016-09-08 Shimano Inc. Elektrischer Fahrradhinterumwerfer
DE102016001333A1 (de) 2015-03-06 2016-09-08 Shimano Inc. Elektrische fahrradkomponentenanordnung
TWI824983B (zh) 2015-03-06 2023-12-01 日商島野股份有限公司 自行車電組件
US10029754B2 (en) 2015-03-06 2018-07-24 Shimano Inc. Bicycle electrical system
WO2016160923A1 (en) * 2015-03-31 2016-10-06 Janssen Biotech, Inc Antigen binding proteins
JP7128460B2 (ja) 2015-06-04 2022-08-31 国立研究開発法人国立精神・神経医療研究センター Il-6阻害剤を有効成分とする精神疾患治療剤
JP7026634B2 (ja) 2016-03-30 2022-02-28 エフ.ホフマン-ラ ロシュ アーゲー B細胞培養法
WO2017181031A2 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
KR102382895B1 (ko) 2016-07-12 2022-04-08 카이트 파마 인코포레이티드 항원 결합 분자 및 그의 사용 방법
WO2018122147A1 (en) 2017-01-02 2018-07-05 F. Hoffmann-La Roche Ag B-cell cultivation method
EP3576790A4 (en) 2017-02-01 2020-12-23 Yale University TREATMENT OF DIURETIC RESISTANCE
EP3589725A1 (en) * 2017-02-28 2020-01-08 Vib Vzw Means and methods for oral protein delivery
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
JP6978516B2 (ja) 2017-05-19 2021-12-08 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 胸腺細胞上清を産生するための方法
EP3634477A4 (en) * 2017-06-06 2021-03-03 The Regents of the University of California IMMUNOASSAY FOR HUMANESE ERYTHROFERRON
KR20200047606A (ko) * 2017-09-13 2020-05-07 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Il-6r 항체와 이의 항원 결합 단편 및 의학적 용도
EP3698808A4 (en) 2017-10-20 2021-07-14 Hyogo College Of Medicine MEDICAL COMPOSITION CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES FOR THE PREVENTION OF POSTOPERATIVE ADHESION
EP3717632B1 (en) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG B-cell cultivation method
EP3737414A4 (en) * 2018-01-04 2022-02-23 Vitaeris, Inc. USE OF ANTI-IL-6 ANTIBODIES SUCH AS CLAZAKIZUMAB TO DESENSITIZE SOLID ORGAN TRANSPLANT RECIPIENTS AND/OR TO PREVENT, STABILIZE OR REDUCE ANTIBODY-MEDIATED REJECTION (ABMR)
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
WO2020006469A1 (en) * 2018-06-29 2020-01-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating and reducing traumatic brain injury-associated impairments using sgp130
CN109517064B (zh) * 2018-10-10 2020-05-08 北京汇智和源生物技术有限公司 白介素-6的人源化单克隆抗体、其编码基因及应用
WO2020097566A1 (en) 2018-11-08 2020-05-14 Cedars-Sinai Medical Center Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients
BR112021010615A2 (pt) * 2018-12-20 2021-11-03 Cedars Sinai Medical Center Clazakizumab no tratamento de rejeição crônica de transplante de órgãos mediada por anticorpos
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗cgrp抗体を用いた頭痛の急性治療及び迅速治療
US20220306734A1 (en) 2019-07-24 2022-09-29 H. Lundbeck A/S Anti-mglur5 antibodies and uses thereof
WO2021154530A1 (en) * 2020-01-27 2021-08-05 Vanderbilt University Human anti-dengue antibodies and methods of use therefor
CN111228480A (zh) * 2020-02-24 2020-06-05 浙江正熙生物医药有限公司 抗人TNF-α抗体在制备用于治疗病毒感染的药物中的应用
BR102020007149A8 (pt) 2020-04-06 2023-09-26 H Lundbeck As Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
WO2022054565A1 (ja) 2020-09-08 2022-03-17 デクソンファーマシューティカルズ株式会社 サイトカインストーム抑制剤、サイトカインストーム抑制剤の使用方法およびスクリーニング方法
CA3203780A1 (en) * 2021-01-29 2022-08-04 Amgen Inc. Materials and methods for monitoring cancer by administering an anti-mcl1 antibody
JP6974892B1 (ja) 2021-05-27 2021-12-01 デクソンファーマシューティカルズ株式会社 癌悪液質の改善剤および癌悪液質の改善方法
CA3229059A1 (en) 2021-08-27 2023-03-02 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies
CN115819578B (zh) * 2022-10-29 2023-08-18 武汉爱博泰克生物科技有限公司 高亲和力Human IL-5兔单克隆抗体及其应用
CN116715763B (zh) * 2022-11-22 2023-11-24 武汉爱博泰克生物科技有限公司 Mouse IL-6兔单克隆抗体对及其制备方法和应用
CN117797317A (zh) * 2024-02-29 2024-04-02 四川大学 一种肽微球-壳聚糖复合材料的制备方法及其产品和应用

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554513A (en) * 1979-11-21 1996-09-10 Yeda Research & Development Co. Ltd. Production of recombinant human interferon-beta2
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
IL88375A (en) * 1988-11-14 1995-07-31 Yeda Res & Dev Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5202422A (en) 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
ES2103770T3 (es) 1990-11-26 1997-10-01 Akzo Nobel Nv Procedimiento de produccion de anticuerpos monoclonales.
CA2104958A1 (en) * 1991-03-07 1992-09-08 Jean C. Nichols Use of cell surface receptor targeted molecules for the treatment of viral diseases
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
RU2139351C1 (ru) * 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp gp130蛋白質に対するモノクロ−ナル抗体
WO1994004659A1 (en) * 1992-08-21 1994-03-03 United States Of America, As Represented By The Secretary, Department Of Health & Human Services A novel b-lymphoma cell line and antigen
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
TW458985B (en) * 1993-05-31 2001-10-11 Chugai Pharmaceutical Co Ltd Reconstructed human antibody against human interleukin-6
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
FR2707882B1 (fr) * 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
US5882872A (en) * 1994-04-28 1999-03-16 Kudsk; Kenneth A. Use of an IL-6 assay for predicting the development of post-trauma complications
US5646005A (en) * 1994-04-28 1997-07-08 Kudsk; Kenneth A. Use of an IL-6 assay for predicting the development of post-trauma complications
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
DE69534075T2 (de) * 1994-06-07 2005-07-21 Chugai Seiyaku K.K. Vorbeugungs- und heilmittel für erkrankungen, die durch fibrin- oder thrombusbildung hervorgerufen werden
US5545623A (en) * 1994-06-10 1996-08-13 Akira Matsumori Method of inhibiting secretion of inflammatory cytokines
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
EP0791359A4 (en) * 1994-10-21 2002-09-11 Chugai Pharmaceutical Co Ltd MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES
JP4079461B2 (ja) * 1994-12-29 2008-04-23 中外製薬株式会社 Il−6アンタゴニストを含んでなる抗腫瘍剤の作用増強剤
ES2264135T3 (es) * 1995-02-13 2006-12-16 Chugai Seiyaku Kabushiki Kaisha Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6.
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
DE69713336T2 (de) * 1996-03-30 2002-12-05 Science Park Raf S P A Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren
US5854398A (en) * 1996-07-25 1998-12-29 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof
DK0826696T3 (da) * 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
DE69839992D1 (de) * 1997-03-21 2008-10-23 Chugai Pharmaceutical Co Ltd Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
TR199902800T2 (xx) * 1997-05-15 2000-04-21 Chugai Seiyaku Kabushiki Kaisha Ka�eksiyi tedavi edici madde.
DE19725586C2 (de) * 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
SG152917A1 (en) * 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
PL201461B1 (pl) * 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny
JP2002512776A (ja) * 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6838290B2 (en) * 1998-08-21 2005-01-04 Immunex Corporation Methods for screening compounds that affect IL-1 epsilon activity
US7345217B2 (en) 1998-09-22 2008-03-18 Mendel Biotechnology, Inc. Polynucleotides and polypeptides in plants
WO2000018435A1 (de) * 1998-09-25 2000-04-06 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
ATE422205T1 (de) * 1998-10-21 2009-02-15 Chugai Pharmaceutical Co Ltd Verfahren zum screenen von verbindungen, die die produktion von entzündungszytokinen inhibieren
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6419944B2 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US6939547B2 (en) * 2000-07-31 2005-09-06 The United States Of America As Represented By The Department Of Health And Human Services Specific binding agents for KSHV vIL-6 that neutralize a biological activity
CN1308447C (zh) 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
EP1334731B1 (en) * 2000-10-25 2008-02-27 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤
AU2000279624A1 (en) * 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
IL139380A0 (en) * 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2002240194A1 (en) * 2001-02-02 2002-08-19 Rutgers, The State University Non-cytotoxic pap mutants
US7169573B2 (en) * 2001-02-20 2007-01-30 Oklahoma Medical Research Foundation Method for monitoring coagulability and hypercoagulable states
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
JP2003066047A (ja) 2001-06-14 2003-03-05 Matsushita Electric Ind Co Ltd 免疫反応測定方法及びそれに用いる免疫反応測定用試薬
IL159771A0 (en) * 2001-07-09 2004-06-20 Combinatorx Inc Combinations for the treatment of inflammatory disorders
US20030219839A1 (en) * 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
KR20100120246A (ko) * 2001-11-14 2010-11-12 센토코 오르토 바이오테크 인코포레이티드 항 il-6 항체, 조성물, 방법 및 용도
AU2002357759A1 (en) * 2001-11-21 2003-06-10 Mark W. Appelby Manipulation of cytokine levels using cd83 gene products
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
GB0209884D0 (en) 2002-04-30 2002-06-05 Ares Trading Sa Proteins
US20030229030A1 (en) * 2002-06-11 2003-12-11 Theoharides Theoharis C. Method of treating interleukin-6-mediated inflammatory diseases
BR0311799A (pt) * 2002-06-14 2005-05-10 Immunomedics Inc Anticorpo monoclonal hpam4
WO2004003544A1 (en) * 2002-06-26 2004-01-08 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders
US20040086979A1 (en) * 2002-08-15 2004-05-06 Dongxiao Zhang Humanized rabbit antibodies
US20060078532A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US7482436B2 (en) * 2002-08-30 2009-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of antibody
JP4790413B2 (ja) 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド 抗体療法
EP2258724A1 (en) * 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulating immune responses using multimerized anti-CD83 antibodies
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
CA2510715A1 (en) * 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1607100A4 (en) * 2003-02-24 2007-06-13 Chugai Pharmaceutical Co Ltd MEDICAMENT WITH AN INTERLEUKIN-6 ANTAGONIST FOR BACK-MARGIN INJURIES
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
KR100912381B1 (ko) * 2003-06-19 2009-08-19 타녹스 인코퍼레이티드 응고 관련 질병을 치료하기 위한 조성물 및 방법
US20050048578A1 (en) 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
EP1651266B1 (en) * 2003-07-25 2010-03-03 Laboratorios Silanes, S.A. de C.V. Administration of anti-tnf-alpha f(ab')2 antibody fragments
WO2005016950A1 (en) * 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2005037314A1 (en) * 2003-08-20 2005-04-28 Centocor, Inc. Method for generating antibodies
CN1871259A (zh) * 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
EP1664774A4 (en) * 2003-08-29 2007-06-27 Centocor Inc RAPID MEANS FOR OBTAINING HIGH-EXPRESSION CLONES OF MAMMALIAN CELLS, ACCORDING TO A METHYLCELLULOSE SCREENING METHOD AND IMMUNOPRECIPITATION
US7634360B2 (en) * 2003-09-23 2009-12-15 Prediction Sciences, LL Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
US7392140B2 (en) * 2003-09-23 2008-06-24 Prediction Sciences, Llc Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
NZ546557A (en) * 2003-10-17 2010-01-29 Chugai Pharmaceutical Co Ltd Therapeutic agent for mesothelioma comprising interleukin-6
EP1678314B1 (en) 2003-10-22 2012-09-05 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US8617550B2 (en) * 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
JP2008504363A (ja) * 2004-06-29 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー P2x7受容体のベンズアミド阻害剤を利用する併用療法
CA2574496C (en) * 2004-07-22 2014-04-22 Early Detection, Llc Methods for diagnosis using anti-cytokine receptor antibodies
US20060051348A1 (en) * 2004-09-09 2006-03-09 Jorn Gorlach Method of producing a plurality of isolated antibodies to a plurality of cognate antigens
US20070036788A1 (en) * 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
WO2006047639A2 (en) * 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
ITRM20050103A1 (it) * 2005-03-10 2006-09-11 Rocco Savino Associazione di antagonisti della interleuchina 6 e farmaci antiproliferativi.
US20080033027A1 (en) 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
US20070048306A1 (en) * 2005-08-30 2007-03-01 Giles-Komar Jill M Method for generating anti-variable region monoclonal antibodies
JP2009526087A (ja) 2005-12-22 2009-07-16 アナボレックス, インコーポレイテッド 悪液質の予防および処置のための組成物および方法
CN101346395A (zh) 2005-12-30 2009-01-14 默克专利有限公司 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
WO2007104529A2 (en) * 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
MX2008014692A (es) 2006-05-19 2009-08-18 Alder Biopharmaceuticals Inc Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno.
US7655417B2 (en) 2006-05-31 2010-02-02 Hanwha Chemical Corporation VCAM-1 specific monoclonal antibody
MY159787A (en) * 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008019061A2 (en) 2006-08-03 2008-02-14 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
ES2902063T3 (es) * 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Proteínas de unión a interleucina-13
WO2008042611A2 (en) * 2006-09-29 2008-04-10 Centocor, Inc. Method of using il6 antagonists with mitoxantrone for prostate cancer
CA2667808A1 (en) 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US20090238825A1 (en) 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8252286B2 (en) * 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
AU2008254578B2 (en) 2007-05-21 2013-06-06 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
WO2008144763A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
WO2008156807A2 (en) * 2007-06-19 2008-12-24 The Johns Hopkins University Antithrombotic agents and methods of use thereof
US8277804B2 (en) 2008-05-21 2012-10-02 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
JP5789192B2 (ja) * 2008-11-13 2015-10-07 フェムタ ファーマシューティカルズ インコーポレイテッドFemta Pharmaceuticals,Inc. ヒト化抗il−6抗体
US10227404B2 (en) 2008-11-25 2019-03-12 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8420089B2 (en) * 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) * 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
EP2361095B1 (en) 2008-11-25 2017-12-20 AlderBio Holdings LLC Antagonists of il-6 to raise albumin and/or lower crp
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) * 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
JP2012533548A (ja) 2009-07-14 2012-12-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組成物における黄色形成および過酸化物形成を阻害する方法
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504030A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP
RU2013126477A (ru) 2010-11-08 2014-12-20 Дженентек, Инк. Вводимые подкожно антитела против рецептора il-6
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
WO2015054293A1 (en) 2013-10-07 2015-04-16 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of psoriatic arthritis

Also Published As

Publication number Publication date
AU2008254584B2 (en) 2013-10-03
CN101754772B (zh) 2015-08-19
NZ581596A (en) 2012-02-24
PL3187506T3 (pl) 2019-09-30
WO2008144763A2 (en) 2008-11-27
CA2688146C (en) 2018-03-06
LT2164514T (lt) 2017-03-10
KR101741731B1 (ko) 2017-05-30
NO20093387L (no) 2010-01-15
CA2688146A1 (en) 2008-11-27
ZA200908770B (en) 2018-11-28
JP2019047787A (ja) 2019-03-28
EA200901533A1 (ru) 2010-06-30
ES2721753T3 (es) 2019-08-05
JP6703063B2 (ja) 2020-06-03
CY1119068T1 (el) 2018-01-10
IL235877B (en) 2018-08-30
HK1138796A1 (zh) 2010-09-03
EP3187506A1 (en) 2017-07-05
AU2008254584A1 (en) 2008-11-27
MX2009012492A (es) 2010-01-20
US20150197567A1 (en) 2015-07-16
US7935340B2 (en) 2011-05-03
KR20100028569A (ko) 2010-03-12
JP2017093438A (ja) 2017-06-01
NZ597767A (en) 2013-06-28
SI2164514T1 (sl) 2017-04-26
JP6189274B2 (ja) 2017-08-30
CN101754772A (zh) 2010-06-23
EP2164514B1 (en) 2016-12-14
SG183742A1 (en) 2012-09-27
IL202238A0 (en) 2010-06-16
TR201905366T4 (tr) 2019-05-21
DK2164514T3 (en) 2017-02-27
TW201441257A (zh) 2014-11-01
CO6241159A2 (es) 2011-01-20
HUE043782T2 (hu) 2019-09-30
JP2010527615A (ja) 2010-08-19
DK3187506T3 (da) 2019-06-11
HRP20170038T1 (hr) 2017-07-14
US10800841B2 (en) 2020-10-13
CN105001332A (zh) 2015-10-28
HRP20191013T1 (hr) 2019-08-23
PL2164514T3 (pl) 2017-08-31
IL202238A (en) 2016-04-21
IL271270A (en) 2020-01-30
JP6412543B2 (ja) 2018-10-24
TW200902550A (en) 2009-01-16
US20090028784A1 (en) 2009-01-29
MX349322B (es) 2017-07-21
US20100290993A1 (en) 2010-11-18
KR101829776B1 (ko) 2018-02-19
KR20150073881A (ko) 2015-07-01
KR20170062546A (ko) 2017-06-07
ES2610607T3 (es) 2017-04-28
CY1121779T1 (el) 2020-07-31
EP3187506B1 (en) 2019-03-27
WO2008144763A3 (en) 2009-01-22
CA2993715A1 (en) 2008-11-27
KR101615715B1 (ko) 2016-04-27
IL261019B (en) 2019-12-31
NO20190984A1 (no) 2010-01-15
NO344119B1 (no) 2019-09-09
EP2164514A2 (en) 2010-03-24
SI3187506T1 (sl) 2019-08-30
TWI561530B (en) 2016-12-11
EP2164514A4 (en) 2012-08-29
CN105001332B (zh) 2018-12-04
BRPI0811782A2 (pt) 2019-02-26
LT3187506T (lt) 2019-04-25
PT3187506T (pt) 2019-04-24
JP5833823B2 (ja) 2015-12-16
PT2164514T (pt) 2017-02-16
IL261019A (en) 2018-10-31
US20180100013A1 (en) 2018-04-12
TWI617576B (zh) 2018-03-11
US9771421B2 (en) 2017-09-26
JP2015044818A (ja) 2015-03-12

Similar Documents

Publication Publication Date Title
US11827700B2 (en) Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies
US10800841B2 (en) Methods of treating autoimmunity using specific anti-IL-6 antibodies
US10913794B2 (en) Antibodies to IL-6 and use thereof
AU2014200210A1 (en) Antibodies to IL-6 and use thereof